USFDA issues warning letter to Lupin's Goa, Indore plants

The US Food and Drug Administration (USFDA) has issued a warning letter to Lupin for violation of current good manufacturing practice norms at two of its manufacturing facilities in Goa and Indore.

In a letter to Lupin Managing Director Nilesh Gupta, USFDA said inspectors during an inspection from March 27 to April 7, found significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.

"Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," it noted.

Elaborating on the violations at the Goa plant, USFDA said the company failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.

"Your firm frequently invalidated initial out-of- specification (OOS) laboratory results without an adequate investigation that addressed potential manufacturing causes," USFDA said.

Besides, the Mumbai-based drug firm failed to establish appropriate time limits for the completion of each phase of production to assure the quality of the drug product, it added.

On Lupin's Pithampur (Indore) plant, the US health regulator said the company invalidated initial OOS laboratory results without adequate investigations.

"Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to assist your firm in meeting CGMP requirements," USFDA said.

The company should immediately and comprehensively assess its global manufacturing operations to ensure that systems and processes, and ultimately, the products manufactured, conform to FDA requirements at all sites, it added.

Until the company corrects all violations and deviations completely and the USFDA confirms its compliance with CGMP, it may withhold approval of any new applications, it said.

Failure to correct these violations may also result in FDA refusing admission of articles manufactured at Lupin's Goa and Pithampur plants into the United States, it added.

Lupin shares today ended 0.81 per cent up at Rs 829.30 apiece on the BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel